宫颈癌肝转移的治疗研究进展

谢尚丹; 胡群超; 诸海燕

doi:10.12449/JCH240704

宫颈癌肝转移的治疗研究进展

DOI: 10.12449/JCH240704

1.
同济大学附属妇产科医院妇科，上海 201204
2.
上海交通大学医学院附属同仁医院放疗科，上海 200000

基金项目:

国家自然科学基金面上项目 (82272778)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：谢尚丹负责文献调研，分析资料，撰写初稿；胡群超参与收集数据，修改论文；诸海燕拟订写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
诸海燕， zhuhaiyandoc@sina.com （ORCID： 0000-0002-1030-4601）

计量
- 文章访问数: 742
- HTML全文浏览量: 95
- PDF下载量: 32
- 被引次数: 0
出版历程
- 收稿日期: 2024-04-10
- 录用日期: 2024-05-11
- 出版日期: 2024-07-25

Research advances in the treatment of cervical cancer with liver metastasis

1.
Department of Gynecology，The Obstetrics & Gynecology Hospital of Tongji University，Shanghai 201204，China
2.
Department of Radiotherapy，Tongren Hospital，Shanghai Jiaotong University School of Medicine，Shanghai 200000，China

Research funding:

General Project of National Natural Science Foundation of China (82272778)

More Information

Corresponding author: ZHU Haiyan， zhuhaiyandoc@sina.com （ORCID： 0000-0002-1030-4601）

摘要

摘要: 宫颈癌肝转移的发生率较低，常伴有其他部位的转移，预后差。针对宫颈癌肝转移的治疗需综合患者一般情况、病灶分布、初始治疗方式和预期生存目标等多种因素，制订个体化治疗方案，以达到延长患者生存时间、提高生存质量的目的。本文主要结合国内外研究探讨宫颈癌肝转移的临床特征、治疗现状以及预后情况。
- 宫颈肿瘤 /
- 肿瘤转移 /
- 肝 /
- 治疗学
Abstract: Though liver metastasis of cervical cancer has a relatively low incidence rate， it is often accompanied by metastasis in other sites and thus has a poor prognosis. For the patients with liver metastasis of cervical cancer， it is necessary to formulate individualized treatment regimens based on various factors such as general status， lesion distribution， initial treatment modality， and life expectancy， so as to prolong the overall survival of patients and improve their quality of life. With reference to related studies in China and globally， this article reviews the clinical features， treatment， and prognosis of cervical cancer with liver metastasis.
- Uterine Cervical Neoplasms /
- Neoplasm Metastasis /
- Liver /
- Therapeutics

HTML全文

参考文献(41)

[1]	SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
[2]	ZHANG Y, GUO Y, ZHOU X, et al. Prognosis for different patterns of distant metastases in patients with uterine cervical cancer: A population-based analysis[J]. J Cancer, 2020, 11( 6): 1532- 1541. DOI: 10.7150/jca.37390.
[3]	LI PP, SU YH, ZHANG MZ. Hepatic metastases after cervical cancer surgery: clinical analysis of 13 cases[J]. Chin J Obstetr Gynecol, 2020, 55( 4): 266- 272. DOI: 10.3760/cma.j.cn112141-20200114-00033. 李盼盼, 苏玥辉, 张梦真. 子宫颈癌术后肝转移13例临床分析[J]. 中华妇产科杂志, 2020, 55( 4): 266- 272. DOI: 10.3760/cma.j.cn112141-20200114-00033.
[4]	LIU H, YE XS, LI D, et al. Incidence, clinical risk and prognostic factors for liver metastasis in patients with cervical cancer: A population-based retrospective study[J]. BMC Cancer, 2021, 21( 1): 421. DOI: 10.1186/s12885-021-08127-6.
[5]	KIM GE, LEE SW, SUH CO, et al. Hepatic metastases from carcinoma of the uterine cervix[J]. Gynecol Oncol, 1998, 70( 1): 56- 60. DOI: 10.1006/gyno.1998.5037.
[6]	GARDNER AB, CHARO LM, MANN AK, et al. Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: Most common locations and outcomes[J]. Clin Exp Metastasis, 2020, 37( 1): 107- 113. DOI: 10.1007/s10585-019-10007-0.
[7]	DING X, WANG QY, MA LL, et al. Analysis of risk factors of postoperative liver metastasis in patients with early cervical cancer[J]. Chin J Woman Child Health Res, 2023, 34( 6): 95- 101. DOI: 10.3969/j.issn.1673-5293.2023.06.014. 丁鑫, 王乾印, 马亮亮, 等. 早期子宫颈癌患者术后发生肝转移的危险因素分析[J]. 中国妇幼健康研究, 2023, 34( 6): 95- 101. DOI: 10.3969/j.issn.1673-5293.2023.06.014.
[8]	PARK KJ. Cervical adenocarcinoma: Integration of HPV status, pattern of invasion, morphology and molecular markers into classification[J]. Histopathology, 2020, 76( 1): 112- 127. DOI: 10.1111/his.13995.
[9]	DOLL KM. Investigating Black-White disparities in gynecologic oncology: Theories, conceptual models, and applications[J]. Gynecol Oncol, 2018, 149( 1): 78- 83. DOI: 10.1016/j.ygyno.2017.10.002.
[10]	YU LL, SABATINO SA, WHITE MC. Rural-urban and racial/ethnic disparities in invasive cervical cancer incidence in the United States, 2010-2014[J]. Prev Chronic Dis, 2019, 16: E70. DOI: 10.5888/pcd16.180447.
[11]	SCATCHARD K, FORREST JL, FLUBACHER M, et al. Chemotherapy for metastatic and recurrent cervical cancer[J]. Cochrane Database Syst Rev, 2012, 10( 10): CD006469. DOI: 10.1002/14651858.CD006469.pub2.
[12]	MOORE DH, BLESSING JA, MCQUELLON RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study[J]. J Clin Oncol, 2004, 22( 15): 3113- 3119. DOI: 10.1200/JCO.2004.04.170.
[13]	LONG HJ 3, BUNDY BN, GRENDYS EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study[J]. J Clin Oncol, 2005, 23( 21): 4626- 4633. DOI: 10.1200/JCO.2005.10.021.
[14]	ABU-RUSTUM NR, YASHAR CM, AREND R, et al. NCCN Guidelines^® Insights: Cervical Cancer, Version 1.2024[J]. J Natl Compr Canc Netw, 2023, 21( 12): 1224- 1233. DOI: 10.6004/jnccn.2023.0062.
[15]	MONK BJ, SILL MW, BURGER RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A gynecologic oncology group study[J]. J Clin Oncol, 2009, 27( 7): 1069- 1074. DOI: 10.1200/jco.2008.18.9043.
[16]	TEWARI KS, SILL MW, PENSON RT, et al. Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial(Gynecologic Oncology Group 240)[J]. Lancet, 2017, 390( 10103): 1654- 1663. DOI: 10.1016/S0140-6736(17)31607-0.
[17]	ZHU J, SONG CY, ZHENG Z, et al. Anlotinib in Chinese patients with recurrent advanced cervical cancer: A prospective single-arm, open-label phase II trial[J]. Front Oncol, 2021, 11: 720343. DOI: 10.3389/fonc.2021.720343.
[18]	XU Q, WANG JJ, SUN Y, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: A multicenter, single-arm, prospective phase II trial[J]. J Clin Oncol, 2022, 40( 16): 1795- 1805. DOI: 10.1200/jco.21.02091.
[19]	LAN CY, SHEN JX, WANG Y, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer(CLAP): A multicenter, open-label, single-arm, phase II trial[J]. J Clin Oncol, 2020, 38( 34): 4095- 4106. DOI: 10.1200/jco.20.01920.
[20]	Society of Gynecological Oncology of Chinese Society of Clinical Oncology. Chinese expert consensus on the clinical applications of anti-angiogenic small molecule tyrosine kinase inhibitors in recurrent, metastatic or advanced gynecological tumors(2022 edition)[J]. Chin J Oncol Prev Treat, 2023, 15( 1): 1- 10. DOI: 10.3969/j.issn.1674-5671.2023.01.01. 中国临床肿瘤协会(CSCO)妇科肿瘤专家委员会. 抗血管生成小分子酪氨酸激酶抑制剂在复发转移或晚期妇科肿瘤临床应用的中国专家共识(2022版)[J]. 中国癌症防治杂志, 2023, 15( 1): 1- 10. DOI: 10.3969/j.issn.1674-5671.2023.01.01.
[21]	VERGOTE I, VAN NIEUWENHUYSEN E, O’CEARBHAILL RE, et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: Results from the innovaTV 205/GOG-3024/ENGOT-cx8 study[J]. J Clin Oncol, 2023, 41( 36): 5536- 5549. DOI: 10.1200/jco.23.00720.
[22]	CHUNG HC, ROS W, DELORD JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study[J]. J Clin Oncol, 2019, 37( 17): 1470- 1478. DOI: 10.1200/jco.18.01265.
[23]	NAUMANN RW, HOLLEBECQUE A, MEYER T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 trial[J]. J Clin Oncol, 2019, 37( 31): 2825- 2834. DOI: 10.1200/jco.19.00739.
[24]	TEWARI KS, MONK BJ, VERGOTE I, et al. Survival with cemiplimab in recurrent cervical cancer[J]. N Engl J Med, 2022, 386( 6): 544- 555. DOI: 10.1056/NEJMoa2112187.
[25]	COLOMBO N, DUBOT C, LORUSSO D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer[J]. N Engl J Med, 2021, 385( 20): 1856- 1867. DOI: 10.1056/NEJMoa2112435.
[26]	LOU HM, CAI HB, HUANG X, et al. Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer(COMPASSION-13): A phase 2 study[J]. Clin Cancer Res, 2024, 30( 8): 1501- 1508. DOI: 10.1158/1078-0432.CCR-23-3162.
[27]	Society of Onco-Endocrinology of Chinese Anti-Cancer Association. Chinese expert consensus on immunotherapy for gynecological malignant tumors(2023 edition)[J]. China Oncol, 2023, 33( 10): 954- 968. DOI: 10.19401/j.cnki.1007-3639.2023.10.008. 中国抗癌协会肿瘤内分泌专业委员会. 妇科恶性肿瘤免疫治疗中国专家共识(2023年版)[J]. 中国癌症杂志, 2023, 33( 10): 954- 968. DOI: 10.19401/j.cnki.1007-3639.2023.10.008.
[28]	NANCE ME, BIEDERMANN GB, BHAT AP, et al. Chemorefractory liver metastasis from cervical cancer successfully treated with a combination of yttrium-90 and immunotherapy[J]. Radiol Case Rep, 2020, 15( 8): 1359- 1365. DOI: 10.1016/j.radcr.2020.06.010.
[29]	SONG G. Carrelizumab in the treatment of liver metastasis of cervical cancer: A report of 2 cases[J]. Anhui Med J, 2021, 42( 3): 350- 351. DOI: 10.3969/j.issn.1000-0399.2021.03.030. 宋耕. 卡瑞利珠单抗治疗宫颈癌肝转移2例报道[J]. 安徽医学, 2021, 42( 3): 350- 351. DOI: 10.3969/j.issn.1000-0399.2021.03.030.
[30]	BACALBASA N, BALESCU I, DIMA S, et al. Hepatic resection for liver metastases from cervical cancer is safe and may have survival benefit[J]. Anticancer Res, 2016, 36( 6): 3023- 3027.
[31]	KASEKI H, YASUI K, NIWA K, et al. Hepatic resection for metastatic squamous cell carcinoma from the uterine cervix[J]. Gynecol Oncol, 1992, 44( 3): 284- 287. DOI: 10.1016/0090-8258(92)90059-r.
[32]	TANGJITGAMOL S, LEVENBACK CF, BELLER U, et al. Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: A literature review[J]. Int J Gynecol Cancer, 2004, 14( 3): 399- 422. DOI: 10.1111/j.1048-891x.2004.14326.x.
[33]	TOMITA K, MATSUI Y, UKA M, et al. Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade[J]. Jpn J Radiol, 2022, 40( 10): 1035- 1045. DOI: 10.1007/s11604-022-01335-5.
[34]	HAN K, KIM JH, YANG SG, et al. A single-center retrospective analysis of periprocedural variables affecting local tumor progression after radiofrequency ablation of colorectal cancer liver metastases[J]. Radiology, 2021, 298( 1): 212- 218. DOI: 10.1148/radiol.2020200109.
[35]	WANG Q, LI B, SHI HF, et al. Radiofrequency ablation for metastatic lesions from gynecologic malignancies[J]. Chin J Interv Imaging Ther, 2015, 12( 7): 391- 394. DOI: 10.13929/j.1672-8475.2015.07.002. 王勤, 李斌, 石海峰, 等. 射频消融治疗妇科恶性肿瘤转移性病变[J]. 中国介入影像与治疗学, 2015, 12( 7): 391- 394. DOI: 10.13929/j.1672-8475.2015.07.002.
[36]	ZHANG SY, ZHU GY, LI G, et al. Application of stereotactic body radiation therapy to cancer liver metastasis[J]. Cancer Lett, 2016, 379( 2): 225- 229. DOI: 10.1016/j.canlet.2015.10.029.
[37]	de POOTER JA, MÉNDEZ ROMERO A, WUNDERINK W, et al. Automated non-coplanar beam direction optimization improves IMRT in SBRT of liver metastasis[J]. Radiother Oncol, 2008, 88( 3): 376- 381. DOI: 10.1016/j.radonc.2008.06.001.
[38]	KAGARA N, NAKANO Y, WATANABE A, et al. Curative-intent stereotactic body radiation therapy for residual breast cancer liver metastasis after systemic chemotherapy[J]. Breast Cancer, 2014, 21( 6): 761- 764. DOI: 10.1007/s12282-011-0290-5.
[39]	REDDY AV, MILLS MN, RESHKO LB, et al. Stereotactic body radiation therapy in oligometastatic uterine cancer: Clinical outcomes and toxicity[J]. Cancer Investig, 2020, 38( 8-9): 522- 530. DOI: 10.1080/07357907.2020.1817483.
[40]	LI JB, ZHANG LA, ZHOU YL. Observation on the therapeutic effect of interventional therapy for advanced liver metastasis of cervical cancer[J]. J Front Med, 2016, 6( 14): 174- 175. 李继兵, 张来安, 周杨林. 宫颈癌晚期肝脏转移瘤介入治疗疗效观察[J]. 医药前沿, 2016, 6( 14): 174- 175.
[41]	YIN ZM, TANG HR, LI L, et al. Impact of sites versus number of metastases on survival of patients with organ metastasis from newly diagnosed cervical cancer[J]. Cancer Manag Res, 2019, 11: 7759- 7766. DOI: 10.2147/cmar.s203037.